Assay News and Research

RSS

Biomoda receives U.S patent for cancer and pre-cancer cell based diagnostic assay

Biomoda, Inc. (www.biomoda.com) was today awarded U.S. patent 7,670,799, entitled, "Composition and Method for Making 5, 10, 15, 20- Tetrakis (Carboxyphenyl) Porphine (TCPP)" directed to Biomoda's proprietary TCPP formulation for cancer and pre-cancer cell identification and analysis and a method of making the TCPP formulation.

2 Mar 2010

Corgenix Medical announces the availability of new automation friendly anti-phospholipid assay format

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format.

2 Mar 2010

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

Spectral Diagnostics Inc., a company developing products for the treatment of sepsis, today announced that the U.S. Food and Drug Administration has granted Investigational Device Exemption (IDE) approval for Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, allowing the Company to conduct a pivotal trial in the United States.

2 Mar 2010

Study results of new PCR technology that reports mutations associated with FXS announced

Asuragen, Inc. announced today the results of a collaborative study with scientists at the M.I.N.D. Institute at the University of California Davis evaluating a new PCR technology that reproducibly reports mutations associated with Fragile X syndrome (FXS).

2 Mar 2010

febit releases updated Geniom Biochip containing 58 new miRNA sequences

febit today announced that an updated version of the company's Geniom Biochip containing 58 new discovered sequences in addition to all of the Homo sapiens microRNAs (miRNA) from miRBase version 14 is now available for cancer research. The 58 new miRNA sequences were found by deep sequencing in a miRNA discovery study performed on an Applied Biosystems SOLiD 3 sequencing system. All 58 miRNAs have been validated using the ABI TaqMan miRNA qRT-PCR assay and are now available for further studies using febit's microarray technology for miRNA-profiling.

2 Mar 2010

BCRI study evaluates the effect of high-doses of vitamin C on inhibition of new blood vessel growth

Bio-Communications Research Institute's recent research study has found that high levels of vitamin C (ascorbate) inhibit the formation of new blood vessel growth to tumors.

27 Feb 2010

Researchers keep wary eye on emerging tick-borne diseases in Missouri

Stories of environmental damage and their consequences always seem to take place far away and in another country, usually a tropical one with lush rainforests and poison dart frogs.

26 Feb 2010

Pall Corporation announces next generation, 96-well AcroPrep Advance filter plates

Pall Corporation, a global leader in filtration, separation and purification, has introduced its next generation 96-well filter plate that delivers consistency and reproducibility in applications, such as neonatal screening and multiplexing. The Pall AcroPrep Advance filter plate employs new design features that provide uniform filtration rates, lowers hold-up volumes and ensures consistent sample/bead recovery from the wells.

From Pall Corporation 26 Feb 2010

PharmAthene awarded total of $78.4M in additional funding to develop SparVax vaccine

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority has modified its existing research and development contract with PharmAthene providing for up to a total of $78.4 million in additional funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government, to support the continued advanced development of SparVax™, a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National Stockpile.

24 Feb 2010

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference “Tolerance and Autoimmunity” being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled “IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates” was made by Idera scientists.

24 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

SRI International awarded $3.8M BARDA contract to develop a radiation assessment device

SRI International, an independent nonprofit research and development institute, has received a $3.8M contract from the Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA). SRI will research and develop a device to triage individuals who may have been exposed to ionizing radiation after a radiological or nuclear incident.

24 Feb 2010

FDA grants EUA for Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay in CLIA high complexity laboratories

Longhorn Vaccines & Diagnostics today announced it has been granted Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ in CLIA high complexity laboratories. . The Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ is a ready-use assay that requires no mixing prior to use and has been authorized for use on the ABI 7500.

24 Feb 2010

New genetic analysis system for forensic DNA testing laboratories launched

Life Technologies Corporation today announced the launch of a new genetic analysis system designed to optimize data quality and deliver increased reliability, performance, quality assurance and ease-of-use specifically for forensic DNA testing laboratories.

24 Feb 2010

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Diagnostic Hybrids, a Quidel Company has received emergency use authorization from the U.S. Food and Drug Administration for its D3® UltraTM 2009 H1N1 Influenza A Virus ID Kit, a monoclonal antibody fluorescent staining kit for the specific identification of 2009 H1N1 influenza A in direct patient specimens or incubated tissue cultures.

23 Feb 2010

BD Biosciences initiates next-generation flow cytometer

BD Biosciences, a segment of BD, announced today the launch of the BD FACSAria™ III Cell Sorting System, a next-generation flow cytometer with the ability to run complex multicolor experiments using up to six lasers.

From BD (Becton, Dickinson and Company) 23 Feb 2010

New guidance document to prevent food allergies

For the first time, national authorities carrying out official food allergen controls have a common basis for accepting validated testing methods. Consumers allergic to certain food ingredients will benefit from an increased level of protection by the availability of harmonised and reliable testing methods, and international trade will be facilitated by applying mutually-agreed testing protocols.

19 Feb 2010

Gentel Biosciences launches integrated Proteomics Multi-System

Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing “scan-to-analysis” functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.

19 Feb 2010

Asuragen announces agreement to develop and manufacture RNA Control Kits for Affymetrix

Asuragen Inc., a leading molecular biology diagnostic company and service provider, today announced an agreement to develop and manufacture RNA Control Kits for Affymetrix. The RNA Control Kit is intended for use with in vitro transcription (IVT) reagent kits for clinical molecular diagnostic applications that Asuragen has licensed and supplied to Affymetrix.

18 Feb 2010

XMRV infection is not linked to chronic fatigue syndrome

Researchers investigating UK samples have found no association between the controversial xenotropic murine leukaemia virus-related virus (XMRV) and chronic fatigue syndrome (CFS).

17 Feb 2010

Assay News and Research

Biomoda receives U.S patent for cancer and pre-cancer cell based diagnostic assay

Corgenix Medical announces the availability of new automation friendly anti-phospholipid assay format

FDA grants approval to Spectral Diagnostics for pivotal trial of Toraymyxin

Study results of new PCR technology that reports mutations associated with FXS announced

febit releases updated Geniom Biochip containing 58 new miRNA sequences

BCRI study evaluates the effect of high-doses of vitamin C on inhibition of new blood vessel growth

Researchers keep wary eye on emerging tick-borne diseases in Missouri

Pall Corporation announces next generation, 96-well AcroPrep Advance filter plates

PharmAthene awarded total of $78.4M in additional funding to develop SparVax vaccine

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

SRI International awarded $3.8M BARDA contract to develop a radiation assessment device

FDA grants EUA for Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay in CLIA high complexity laboratories

New genetic analysis system for forensic DNA testing laboratories launched

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

BD Biosciences initiates next-generation flow cytometer

New guidance document to prevent food allergies

Gentel Biosciences launches integrated Proteomics Multi-System

Asuragen announces agreement to develop and manufacture RNA Control Kits for Affymetrix

XMRV infection is not linked to chronic fatigue syndrome

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News